Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 8 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 10 | adrenocortical insufficiency is allowed | 25 |
| 2 | 6 | 2 | adrenocortical insufficiency is allowed . | 4 | |
| 3 | 9 | the use of inhaled corticosteroids and mineralocorticoids e . g . | 2 | adrenocortical insufficiency is allowed r n patients who receive low dose supplemental corticosteroids for adrenocortical insufficiency are allowed | 1 |
| 4 | 21 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor tnf agents within 2 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 2 | NA | |
| 5 | 1 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids and systemic mineralocorticoids e . g . | 1 | NA | |
| 6 | 2 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 6 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 7 | 3 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea or steroids as computed tomography ct scan contrast premedication may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 8 | 4 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 14 days prior to randomization however r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea or chronic daily treatment with corticosteroids with a dose of = < 10 mg / day methylprednisolone equivalent may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 9 | 5 | patients must not have received treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 4 weeks prior to cycle 1 day 1 exceptions 1 patients may have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea 2 the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 10 | 10 | medication related treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled . r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 11 | 12 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to start of study treatment . r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled . r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 12 | 13 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to study treatment but a . patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled b . the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 13 | 14 | atezolizumab related exclusion treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 a patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled . b the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 14 | 17 | patients who have received treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks before initiation of study treatment r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 15 | 18 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 . patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled . the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 16 | 19 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents = < 2 weeks prior to registration r n note r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids and mineralocorticoids e . g . | 1 | NA | |
| 17 | 22 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents within 2 weeks prior to cycle 1 day 1 r n patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea may be enrolled r n the use of inhaled corticosteroids or mineralocorticoids e . g . | 1 | NA | |
| 18 | 24 | treatment with systemic immunosuppressive medications including but not limited to prednisone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor anti tnf agents = < 14 days prior to randomization exception patients who have received acute low dose systemic immunosuppressant medications e . g . a one time dose of dexamethasone for nausea are eligible the use of inhaled corticosteroids and mineral corticoids e . g . | 1 | NA |